[Asia Economy Reporter Seo So-jeong] Daewoong Pharmaceutical (CEO Jeon Seung-ho) announced on the 9th that Ion Biopharma, its partner in the botulinum toxin treatment business, has received FDA approval for a Phase 2 clinical trial for the preventive treatment of migraines and has begun patient recruitment.
Ion Biopharma plans to conduct the clinical trial targeting 690 adult patients in the United States, Canada, and Australia who experience migraines on 6 or more days per month. This clinical trial aims to simultaneously secure preventive treatment effects for chronic migraine, characterized by headache symptoms on 15 or more days per month, and episodic migraine, with symptoms on fewer than 15 days per month.
Migraine is one of the most common diseases worldwide, affecting approximately 40 million people in the United States and about 1 billion globally. It is estimated that about 2.2 million people in the U.S. suffer from chronic migraine, with many more experiencing episodic migraine.
Ion Biopharma is the exclusive partner holding the rights to approve, import, and sell Daewoong Pharmaceutical’s botulinum toxin products for therapeutic purposes in the U.S., Europe, Canada, and other regions. Starting with the approval of Phase 2 clinical trials for cervical dystonia last year, the company plans to actively conduct clinical trials for therapeutic indications and continuously acquire additional indications for chronic disease treatments.
Park Sung-soo, Head of the Nabota Business Division at Daewoong Pharmaceutical, said, "The botulinum toxin treatment market accounts for more than twice the size of the cosmetic market and is a highly promising field with great growth potential. We expect that by cooperating with Ion Biopharma, we can supply excellent products at reasonable prices to patients in the U.S. and enhance the status of K-bio."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
